This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Ladies and gentlemen, thank you for standing by and welcome to the Silk Road Medical's 2020 Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference call is being recorded. And if you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Ms. Caroline Paul of Investor Relations. Thank you. Please go ahead, Madame.
spk08: Thank you, and thank you all for participating in today's call. Joining me are Erica Rogers, Chief Executive Officer, and Lucas Buchanan, Chief Financial Officer and Chief Operating Officer. Earlier today, Silk Road Medical released financial results for the full year ended December 31st, 2021. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our operating trends and future financial performance, the impact of COVID-19 on our business and prospects for recovery, expense management, expectations for hiring, physician training and adoption, growth in our organization and reimbursement, market opportunity, commercial and international expansion, label expansion, and product and pipeline development are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors section of our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 16, 2020. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, March 1st, 2021. Silk Road Medical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. And with that, I will turn the call over to Erica.
spk06: Thanks, Caroline. Good afternoon, and thank you for joining our fourth quarter year and year-end 2020 earnings call. Joining me is Lucas Buchanan, our Chief Financial Officer and Chief Operating Officer. While 2020 was marked by unprecedented challenges, we would prefer to reflect on the strength and tenacity of our team here at Silk Road Medical and the accomplishments that have paved the way for growth in 2021 and beyond. Throughout the year, we continued our momentum in the United States, expanding our sales team, training new physicians in innovative ways, and meaningfully moving physicians up their adoption curve. These efforts were reinforced by tremendous strides in published clinical evidence, with over 7,000 TCAR procedures' worth of data in peer-reviewed publications. Exiting 2020, physicians performed more than 26,500 TCAR procedures worldwide, with over 10,000 in 2020 alone. We also made meaningful progress on multiple long-term growth and market-expanding initiatives. As part of these endeavors, we recently submitted our PMA supplement for the en route transcarotid stent system, intended to expand indications for use to include the treatment of patients at standard risk for adverse events from carotid endarterectomy. In other words, standard surgical risk. Coming into this year, we are well positioned with a solid commercial, clinical, and financial foundation to focus on the opportunities within our $5 billion addressable market. Turning now to our Q4 results. As we indicated in January, we entered the fourth quarter of 2020 aware of the potential for a resurgence in the pandemic, and that came to bear in the latter part of the quarter. With hospital resources pressured, specifically staff labor and ICU beds, we started to see constraints on elective procedures. That said, for patients with severe carotid artery disease, stroke prevention can only be delayed so long. All in, this translated into solid fourth quarter results in spite of the worsening environment. 2020 revenues were $75 million, up 19% year-over-year, with fourth quarter results of $21 million and year-over-year growth of 13%. Through the year, we expanded our active sales territories from 33 to 40 by year-end and began the first quarter of 2021 with 43 territories. Despite the significant dip in physician training efforts in the second quarter, we were able to train over 350 new physicians in 2020 to reach approximately 1,800 total physicians trained. We also expanded our hospital account base from roughly 640 in the beginning of the year to just over 800 by year end. As a result of our commercial efforts, our growing physician base performed just shy of 2,900 procedures in the fourth quarter and over 10,000 TCAR procedures for the full year. Over the course of 2021, we expect to see continued momentum as the healthcare operating environment normalizes. The key factors governing a return to normal growth are, of course, hospital resources and patient behavior. These are in turn impacted by the pace of virus transmission, the impact of variants, and vaccination efforts. We're cautiously optimistic that normalization will begin in the second quarter, although there are clearly several unknowns. With these caveats in mind, our expectation is for 2021 revenues to be in the range of $102 to $108 million. As we usher in the trans-carotid era, We continue to be focused on U.S. commercial execution with an increasing bias towards driving deeper adoption within our trained physician base. As always, this entails a relentless focus on patient outcomes as we seek to push TCAR towards the standard of care. Over the past five years, we have meticulously built the market's only dedicated carotid commercial infrastructure. amassed an enviable clinical evidence base, and trained a large cohort of physicians. We look forward to leveraging this collective infrastructure as we exit 2020 with just 6% penetration into the estimated U.S. treated patient population and only 2% of the annual diagnosed population. As such, our top two strategic priorities for 2021 are, number one, Continue to focus on U.S. commercial execution and driving the adoption curve. And number two, preparation for a potential standard surgical risk label expansion for the en route stent. At the same time, we are also investing in our long-term growth drivers, which encompass new indications, new products, new therapies, including acute ischemic stroke and international expansion. With respect to our first priority, 2021 marks the third year in a row with U.S. commercial execution as our number one priority, and this is unlikely to change for years to come. We have proven that we can compete and win where so many others have failed in the past against what is now an almost 70-year-old standard of care in carotid endarterectomy. In fact, In a study just published in JAMA Network Open, the authors found the availability of TCAR in a hospital is associated with a significant decrease in the likelihood of major adverse cardiovascular events at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy. In other words, having a less invasive option like TCAR allows for better patient care. Regarding our opportunity to continue moving physicians up the adoption curve, over half of the physicians we've trained through 2020 were trained within the prior eight quarters. As of the fourth quarter of 2020, when we normalize time from training and we look at our top quartile, We are moving physicians from about 1.4 procedures per quarter up to 5.2. We are encouraged by the meaningful progress we have made over a short period of time, and the future is very bright as we look to leverage the foundation we have built. We remain the only TCAR company in the market as we execute towards this Blue Ocean multibillion-dollar opportunity. With respect to our second priority, We've been focused on architecting a regulatory strategy around the standard surgical risk patient population and ensuring we meet the needs of key stakeholders. While there is still plenty of opportunity within the high surgical risk market, we have previously discussed our desire to unlock the remaining one-third of the currently treated U.S. patient population. After careful consideration with key constituents, we are pleased to have recently submitted our PMA supplement for the en route stent intended to expand our indications for use to the standard surgical risk patient population. This is an important first step on our journey to address the full patient population with severe carotid artery disease. From physician training to commercialization efforts to a likely post-market study if the PMA supplement is approved, we will be prepared. to enter an era where TCAR is on an even playing field with carotid endarterectomy in terms of an addressable patient population. With our two top priorities in mind, we enter 2021 with a desire to further accelerate investment in our commercial organization. Going forward, we expect to shift more of our hiring emphasis towards new sales professionals or area managers, who will continue to leverage our strong base of therapy development specialists. In a few moments, Lucas will share more details on our commercial strategies designed to best serve the ongoing interest in TCAR. Turning now to our other long-term growth drivers. With respect to markets outside the U.S., we recently highlighted a conservative international market opportunity of $2.3 billion. which together with the $2.8 billion U.S. market derives a global opportunity of over $5 billion. To put that in perspective, the U.S. is only 10% of the global stroke burden. International expansion remains on the horizon as we make regulatory progress in geographies such as China and Japan, and as we evaluate go-to-market strategies. We are excited about the opportunity to bring TCAR to other corners of the globe where there is both awareness and demand in the physician community. Regarding further development of our pipeline, we remain committed to expanding our proprietary trans-carotid technologies, most notably to address the neurovascular market segment, where we see opportunity for improved clinical outcomes. We are pleased with the progress we are making in acute ischemic stroke and other areas, and we look forward to sharing more details in the future. Finally, we would like to provide a brief update on our voluntary recall of certain lots of our en route transcarotid stent systems, which are manufactured by our partner, Cordis. As we discussed previously, our team reacted swiftly to mitigate risk by recalling the impacted units and launching a comprehensive investigation, and testing effort to identify the root cause. At this point, there have been no reported strokes, deaths, or long-term patient sequelae associated with these units, and we have not received any new complaints related to this issue. Cordis is ramping up its production to replenish our inventories. So, in summary, we remain focused and excited about our potential to drive the UST car market forward as the sole player while we continue to progress our other long-term growth initiatives. With that, I will now turn the call over to Lucas Buchanan, our Chief Financial Officer and Chief Operating Officer.
spk03: Thank you, Erica. Revenue for the three months ended December 31st, 2020 was $21.1 million, a 13% increase from 18.6 million in the same period of the prior year. Growth was again driven by increased adoption of TCAR across an expanding base of hospital accounts, trained physicians, and active sales territories, partially offset by regional headwinds related to COVID-19. Gross margin for the fourth quarter of 2020 was 75 percent, roughly flat compared to the fourth quarter of the prior year, as improvements in productivity were slightly offset by the timing of investments in manufacturing, engineering, and infrastructure projects. Total operating expenses for the fourth quarter of 2020 were $30.9 million, a 44 percent increase from $21.4 million in the fourth quarter of 2019. R&D expenses for the fourth quarter of 2020 were $10.0 million compared to $3.3 million in the fourth quarter of 2019. The increase was primarily driven by the timing of research and development initiatives. Sales, general, and administrative expenses for the fourth quarter of 2020 were $20.9 million compared to $18.2 million in the fourth quarter of 2019. The increase was primarily attributable to expenses related to growth in our commercial team as well as personnel-related expenses. Expense growth was partially offset by the continued reduction in travel, trade show, and other expenses due to COVID-19. We expect continued growth in operating expenses in 2021 as we expand our commercial team and invest in a number of continued and new R&D initiatives. Net loss for the fourth quarter was $16.8 million, or a loss of 49 cents per share, as compared to a net loss of 8.3 million, or a loss of 27 cents per share, for the same period of the prior year. We ended 2020 with $147.5 million of cash, cash equivalents, and short-term investments. Regarding the balance sheet impact of the voluntary recall of certain lots of our en route transcarotid stent systems in the first quarter of 2021, the obligation to customers was recorded as an accrued liability, whereas the replacement product from Cordis is considered a receivable. Turning to our commercial strategy that Erica mentioned earlier and our outlook for 2021, we are focused on accelerating the adoption curve in our now significant trained physician base, as well as being prepared for a potential standard surgical risk indication. With this in mind, over roughly the next two years, we expect to adjust our historical one to two ratio of area managers to therapy development specialists to almost a one to one coverage ratio without significant change to our overall goals for commercial team size. In other words, we will be investing in more sales expertise with more focused territories to complement our excellent clinical support. We expect to end 2021 with over 50 active sales territories, and we are committed to growing our footprint with further territory expansion in 2022. While driving adoption in our trained physician base is our primary focus, We also expect to train approximately 200 new physicians in 2021. We expect our physician base to perform in excess of 14,500 procedures for the year. As a result of our commercial efforts, we expect full year revenue to be in the range of 102 to $108 million, representing growth of 36 to 44% over 2020 revenue of $75.2 million. We are cautiously optimistic with our expectations, recognizing that trends with COVID-19, which are persisting in the first quarter, can alter the timeline to a normalized healthcare operating environment. One final update that I wanted to provide is on our rebranded website that also includes our environmental, social, and governance policies. Our inaugural corporate sustainability report, which we published in the fourth quarter, highlights our dedication to patient safety as well as our commitment to diversity and equal opportunity. Fundamentally, we are in this business to transform and improve lives. We are looking forward to further progress on our status as a socially responsible organization. At this point, I would like to turn the call back to Erica for closing comments.
spk06: Thank you, Lucas. As we reflect on 2020 and the current environment, we are reminded about how far we have come as a company over a relatively short period of time. Just a few years ago, there was no such thing as TCAR, and now we stand well in excess of 25,000 procedures performed to date. We have developed an entirely new market, and in so doing, we have ushered in an entirely new era of trans-carotid therapies. With a tumultuous but rewarding 2020 behind us, I look forward to building upon Silk Road's incredible base of employees, engineering competencies, and deep intellectual property portfolios supporting trans-carotid innovations. This solid foundation positions us well to continue transforming the way we treat patients in order to deliver more value to patients, the healthcare system, and of course, our shareholders. With that, we will now open it up to questions. Operator?
spk01: Ladies and gentlemen, we will open it up for question and answer session. If you wish to ask a question, please press bar one on your telephone. If you wish to cancel your request, you may press the Founder hash key. Please stand by while we compile the Q&A roster. Your first question comes from the line of Bob Hopkins from Bank of America. Your line is now open.
spk04: Okay, thanks for taking the question, and good afternoon. Hi, Bob. Hey, Erica, how are you?
spk07: Good.
spk04: Excellent. Jeff, I want to ask you guys about the PMA that you mentioned in the press release. And I'm just curious, could you give us a sense for what data might be included in that filing and whether or not the big uptick in R&D in the fourth quarter is related to that filing and data collection? Thank you.
spk06: Yeah, sure, Bob. Thank you for the question. And, yeah, we're really pleased to have announced the submission of the PMA supplement for standard risk. And, you know, I think it's obvious that we did not do a prospective clinical trial specifically for this indication. But with that, we're really not going to talk about the contents of the submission itself. We feel it's not prudent to talk about it at this point in the review process by the FDA. And relative to the R&D expense, I'll let Lucas take that question.
spk03: Yeah, I mean, ultimately, Bob, we hope to shed some light on the front part of your question. In terms of the uptick in R&D and Q4, that's part of it. There are other puts and takes related to the timing of R&D broadly defined, including clinical, regulatory, and quality.
spk04: Thanks for that. The two other things I just wanted to get a quick comment on are, you know, you mentioned OUS markets, and I know, you know, reimbursement in Europe is something that, you know, there's obviously a pathway associated with that. So I'm just curious on OUS, is there any kind of preliminary sense you can give for, you know, when you think you'll be – you know, commercial outside the United States. And then it also, Erica, if you don't mind, just, you know, here we are, it's March 1st. You know, things sounded pretty weak in December and January. Have you seen things trough in terms of surgical procedure volumes and start to get better yet? Just a directional sense would be great.
spk06: Sure. Let me take those in reverse order, Bob. So here's what's interesting is our mix of asymptomatic and symptomatic treatment procedures is kind of an interesting barometer. It's an interesting lens to look through for kind of hospital-based procedures. And it's turned out to be a relatively accurate barometer throughout the pandemic, interestingly, watching that mix of asymptomatic and symptomatic change. And so while we saw in January, as you can expect, coming out of the fourth quarter that a mix where, you know, the symptomatic urgent patient population was being treated quite aggressively, we're pleased that as we've moved through the quarter, we're starting to see what we would consider our more normal mix of asymptomatic and symptomatic. So I think that, you know, that's a reassuring sign in the healthcare infrastructure just in general to address that. On the first part of your question on international, you know, for the first time, Bob, we've kind of put a number, albeit a conservative number, on international, which we've done a roll-up, you know, kind of bottoms up across the major markets in which we might consider launching TCAR, and that roll-up is about 2.3 billion in the treated patient population alone. And, of course, we look at Europe, Japan, and China. And the first step for us really is to knock down the regulatory barriers in China and Japan, which we continue to work on and we're pleased with the progress. Meanwhile, we have hired a vice president of international market development who is working closely with Andy Davis, chief commercial officer, to develop the strategies to go forward in some of these markets.
spk04: Oh, okay. Any sense on timelines, though?
spk06: We're not giving any timeline updates specifically yet, Bob.
spk05: Okay. Okay. Great. Thank you.
spk06: Thank you.
spk01: Your next question comes from the line of Robbie Marcus from J.P. Morgan. Your line is now open.
spk00: Great. Thanks for taking the questions. Maybe to follow up on some of those, you know, for the standard risk submission. Was that, you know, at the behest of the FDA? Did you have discussions with them? Maybe you could help us understand what changed from, let's say, JPMorgan or the third quarter earnings call to today that prompted it. And you mentioned it would likely require a post-approval study, you know, what what should we be expecting in terms of size and cost for something like that?
spk06: Sure. Well, let me sort of take those in reverse order, which is that typically a carotid stent PMA would have a kind of requisite post-approval study. And what we saw in our first PMA approval of the en route stent in high surgical risk, Robbie, was a requirement to do what looked like a more real-world study in the post-market environment. And, of course, that was Roadster 2, Roadster 2 with those incredible results in over 600 patients. And so it wouldn't be unusual for the FDA to require a post-approval study for any carotid stent. And so we're kind of preparing for that eventuality. We haven't disclosed any of the specifics on what we might think would be the scope or the cost, and part of that is done in conversation with FDA, as you probably know, kind of mid-review. And so we're not ready to reveal the details yet. In terms of what changed between J.P. Morgan and now really is the submission itself. And while we're not getting specific on exactly when that PMA went in, suffice to say it was after J.P. Morgan, which is why we continue to say we were working on it in discussions with FDA and the other key constituents. Our strategy all along, from the beginning, from the dawn of time, Robbie, was to be in conversations with FDA, with CMS, with the Society of Vascular Surgery and to settle on not only the best approach from a regulatory standpoint, but also to drive adoption and to drive toward a reasonable coverage environment. And so I think without getting into the details, since we're in the review process now, suffice to say that we reached what we felt was a reasonable agreement among the parties.
spk00: Okay. And I'm guessing... we're not going to learn more about what the agreement is until approval?
spk06: Yeah, I think that's a fair assumption, Robbie. You know, I think it would be atypical for any company to kind of reveal the contents of a PMA in advance of approval. And so I think, you know, those details certainly will come into the public light on their own post-approval.
spk00: Got it. Just a few more. One on reimbursement upon hopeful approval. Do you think you would be able to get reimbursement for standard risk right away, or do you think it would be a process that required time after approval?
spk06: Yeah, well, the first step in any coverage environment is approval, right? So we certainly have to knock down... the PMA approval first. But I think it's safe to say we've been in discussions all along with the parties around the table. And so we'll continue to work toward an optimized coverage environment as we seek to get FDA approval.
spk00: Got it. And then last for me, you train around 350 or so docs during 2020. Guidance for 2021 is only for 200 doctors. You know, I imagine part of this is probably due to the soft environment in first quarter, but was hoping you could help us understand the 200 number and where that's coming from. And, Lucas, if you want to put out a first quarter range for the street, I imagine that's probably a big part of the delta between guidance and where street numbers sit. Just thought it would be a good opportunity. Thanks.
spk06: Yeah, I can take the first one on training, Robby. You know, we have said all along that we have been working to kind of lay down the infrastructure of territories, hospitals open, physicians trained. At the end of the day, what we're trying to get at are procedures. And to get at procedures, you need to train physicians. And so coming out of 2020 with roughly 1,800 physicians trained, That's a lot of access to a lot of procedures. And so, as I said in my prepared remarks, our commercial focus is very much about moving those 1,800 up their adoption curve. And this is reflected in the remarks that Lucas made around the sales infrastructure, really making sure that we guide and move each and every one of those physicians trained up their adoption curve. And, of course, the physicians trained in the pandemic environment are you know, potentially need some additional focus, as you can imagine. And so while there are more physicians yet to be trained in terms of getting at kind of the 80% of the procedural volume in the United States, our bias is increasingly more toward moving the existing physicians up the adoption curve, which is part of why the number is around 200 for 2021 guidance.
spk03: Yeah, and just to zoom out a little bit on that, and then I'll get to your guidance question, Robbie. You know, at a high level, when you're going against such an established standard of care and CEA, really we've spent the last many years establishing TCAR, which requires, you know, not only opening accounts and training docs and taking them carefully through their learning curve, but really establishing a published clinical evidence base from which to market with. And so our past has really been about establishing TCAR and establishing this market. And our future is really, we know that therapy works. It delivers incredible outcomes. And so it's more of a commercial focus and driving that adoption curve in this infrastructure that built with outcomes always is the number one goal. With respect to your guidance question, yes, like the rest of the industry, Q1 is COVID-affected. As a reminder, we're an inpatient procedure. There's an urgent part of the business and there's an elective part of the business and the symptomatic versus asymptomatic. And our assumptions are starting in Q2. We start to see a much more normalized operating environment. So if there are, you know, further COVID trends that play out to the downside, that's not necessarily in our guidance. We're assuming a more normal operating environment starting in Q2 and getting incrementally better. And most of that has to do with just kind of the overall engine of medicine and getting patients back into the treatment funnel, back to the diagnosis funnel, getting hospitals coming out of, you know, the funk of COVID. And, you know, that's a little bit unpredictable. I think we believe that, you know, vacations will be a big seasonality impact as everybody wants to go visit their families and get out of town, whether you're a patient or a provider. We've had some weather impacts in Q1, of course. But really, you know, we continue to focus on the setup for long-term growth and feeling really bullish about the business of TCAR and our long-term growth drivers, especially on the heels of this most recent, you know, announcement of a PMA supplement submission, which is really amazing news.
spk00: Great. Thanks a lot.
spk01: Your next question comes from the line of Rick Wise from Stifel. Your line is now open.
spk05: Good afternoon to you both. Erica, you were kind enough to highlight the progress that you've made on the recall, and it was great that, you know, the patient comments and that you had no new complaints. Is it basically resolved now in your mind? And just to amplify a couple of things, You indicated Cordis is ramping production to replenish your inventories. Maybe you can give us some color about how soon you think your inventories will be replenished. And last on that topic, was there an impact in the fourth quarter? Again, remind me, but has there been an impact on January, February volumes from a lack of inventory? I'm just not clear about some of those nuances. Thank you.
spk06: Sure, Rick. I'm happy to address those questions, and thanks very much. So as it relates to the recall, of course, nobody wants to have a recall, but I'm proud of the fact that we responded very quickly, and we were very proactive in that response and getting at the root cause. And so as a result, in many cases, our relationships have actually strengthened as a result of our, you know, conservatism around patient care. To get at the question of whether or not the recall itself impacted procedural volumes or, for that matter, kind of how the fourth quarter ended, I think we can emphatically say no. There was no impact on procedural volumes. Our Our field team and our customers were able to continue to execute the cases that were on the schedule, and we've been very swiftly replacing the inventory at the hospital level as well as our own inventories. Luckily, as a company, we're pretty conservative about the on-hand inventory we carry, which put us in a pretty good spot. And so that's the inventory that we're working to replace swiftly. with Cordis, and they've been a terrific partner, not only in getting to resolution of the matter, but in really ramping production to bring our stock levels back up to where we want them. In terms of whether or not the issue has been resolved, I think it's fair to say we have isolated the root cause. What that means, Rick, is now we're in the process of the corrective actions components here, which is, you know, highly documented process of making sure the corrective actions are in place and that those corrective actions are effective. And so we're in the process of doing all of that, which I consider to be on track.
spk03: Let me just quickly add on the financial aspects of your question. Per my prepared remarks, it's really a balance sheet effect in terms of a liability to our customers to replace those products and a receivable on the Cordis side as we get them replaced from Cordis. And so there's no P&L impact either in Q4 or likely in Q1. And to Erica's point, the main focus is on servicing demand and not going on back order and so far so good. So it's really more a question of building up our safety stock. Yeah, thanks.
spk05: Sure. And apologies for coming back to the standard risk filing. The good news is you won't have to say when you're going to do something, but now we're moving on to phase two of how long is it going to take? And I know it's impossible to know, but I feel like I have to ask. Maybe blame it on your outside consultants. What are your outside consultants saying about the PMA supplements at the current time? Are we thinking it could average? Is this a six-month kind of process, a 12-month kind of process? Can you give us any incremental color just so that we could – roughly frame a reasonable expectation?
spk06: Yeah, Rick, I think it's a fair question, which is the PMA supplement kind of falls under the PMA general category, which is typically a six-month review process. That said, we have not baked in any assumptions around standard surgical risk lift in our guidance for the year. So the 102 to 108 million does not contemplate standard surgical risk commercial activities this calendar year.
spk05: Okay. And just last for me, you called out the JAMA study. I wanted to ask you about that. Gosh, it reads fantastically well for TCAR. And I realize it's, I mean, it's just part of a whole portfolio of studies and data that you have. But is this that, you know, moment where, is that the, you know, the thing that flips adoption more aggressively or is that over dreaming or hoping for something from a specific study? Thank you.
spk06: Sure, Rick, and I'm glad that you caught that paper in JAMA last week, and we felt it was significant enough, obviously, to put a press release around it. It is very big news. And in terms of the light switch phenomenon, you know, we've said this before, that becoming the standard of care is a methodical and careful march with both our physicians and hospitals. We do see this as a unique phenomenon. tailwind because it's really about overall outcomes. It's about hospital efficiencies and better patient care. And so I think it'll have a unique impact. It's probably too soon to measure or to tell you exactly what that impact is, although I assure you our marketing and sales teams are armed and are having those conversations right now. But I think it's safe to say that this business is probably not going to be a light switch phenomenon. It's moving physicians, moving hospitals up the adoption curve methodically.
spk05: Thank you very much.
spk03: Hey, Rick, I just want to add some additional color to Erica's PMA comment. I think, you know, it's at minimum a six-month review cycle. As you know, these PMAs can take significantly longer than that. This is a novel strategy given that we did not do a prospective IDE trial, so it's fair to say it's hard to predict. And I think, as Erica mentioned, the guidance is a function of a lot of different puts and takes focused more around the engine of medicine overall coming out of COVID, hopefully, than any particular nuance around standard surgical risk. There's a lot of preparation, regardless of if and when it's approved. It's not a light switch type of thing. It's something that we'll need to go to market with and talk to physicians about.
spk02: Thanks again.
spk01: Your next question comes from the line of Joanne Wrench from Citibank. Your line is now open.
spk09: Good afternoon, everybody, and thank you for taking my questions. I want to go to a previous question that sort of focuses on the first quarter because I think the way when I look at the model, you're sequentially improving throughout the year, second half stronger than the first half, but it all gets sort of based on that first quarter. Street consensus is around 24 million. Could you please give us sort of a a range of thought on how we're starting the year?
spk03: Yeah, I think that, you know, we've discussed some of the monthly trends in Q4 and alluded to Q1. And I think, you know, that argues for more conservatism on Q1 overall in terms of, you know, sequential experience off of Q4. And I think as we look towards the year, we're really looking at kind of a three-quarter with the second quarter being the path to the beginning of normalization. Third quarter typically has some seasonality. We think the vacation impact might be bigger this year just given what's behind us as a society. And then, you know, so growing from Q2 to Q4 with a fair amount of conservatism on Q1. Obviously, we still have March to go to see how it fully plays out.
spk09: Okay, just to push a little bit further, it sounds like what you're saying, given the trends, first quarter below fourth quarter. I'm trying not to put words in your mouth, but I want to make sure we set this up right.
spk03: I think... That's on the conservative side of conservative, Joanne.
spk09: Okay. Conservative side of conservative. I got it. Can you help us think about how you prepare for standard risk? Is it different? I mean, different training, different physicians, different salespeople? Help us understand that.
spk06: Yeah, sure, Joanne. Hi, and thanks for joining us. So in terms of, you know, how we've been telling the story up till now, it's really been working with our physicians to identify the high surgical risk criteria that qualify a patient for treatment. If and when we obtain the standard surgical risk PMA approval, it will be the first time where a therapy has been on a level playing field with carotid endarterectomy. And so that inherently is going to change the way we talk to our physician customers, where the focus will really be on reasons not to do TCAR versus finding those high surgical risk patients and the high surgical risk criteria. And so we will be working on additional marketing materials, additional training materials for our own team, Obviously, there are labels that get changed that flow through the marketing materials. And so those are all the things that we are doing in the background.
spk09: That's helpful. And my last question is, what other milestones you're in a position to share with us for ischemic strokes?
spk06: You know, Joanne, we continue to be excited by the opportunity. You know, it's a very fast-growing market, as you know. It's highly competitive, as you also know. And so, as a result, you know, we're saving the details until such time that we really kind of have to talk about them. But we're pleased with the progress that we're making, and the progress is really on the clinical and regulatory fronts within R&D at the moment.
spk09: Terrific. Thank you so much, and have a great night.
spk06: Thanks, Joanne.
spk01: Your next question comes from the line of Daniel Antolfi from SVB D-Link. Your line is now open.
spk07: Thank you so much. Good afternoon, everyone. Thanks for taking the questions. Just to follow up on Joanne's question regarding standard risk, and Erica, you alluded to this, but I guess Once you do have standard risk, you're going to – it's kind of like the question might be why not TCAR versus who can get a TCAR versus has to get CEA. So I'm curious about how you're thinking of the sort of halo effect on the total market that standard risk could bring once you have it and how much of an accelerant this is. even just in the existing high-risk indication? That's the first part of the question. I just have one follow-up.
spk06: Yeah, I think, you know, overall, Danielle, it's certainly positive news. And, again, this submission is really the first part of a journey towards standard surgical risk, so we don't want to get too far ahead of ourselves. But I think we've said this all along, Danielle, which is vascular surgeons don't really divide up the world in high surgical risk and standard risk. That's a vernacular that is born out of regulatory and reimbursement policies. And so, you know, what we find ourselves doing now is really having a conversation that is kind of not natural around high surgical risk and standard risk. So this will be, for the first time, putting us on a level playing field. Whether or not that has a halo effect for the overall market opportunity, the number of patients treated, et cetera, I think it's too soon to tell, so I don't want to get ahead of ourselves. I do think there's a tailwind in this JAMA paper that we just talked about, which is the presence of TCAR in an institution improves the outcomes overall, and that coupled with our entry ultimately into standard surgical risk, these are the kinds of tailwinds that will begin to move us toward the standard of care and potentially begin to expand the market.
spk07: Yeah, okay, that makes sense, and that's helpful. And I guess just to get my follow-up, I mean, you kind of answered it already. I'll ask it anyway to see if there's any more color to be gleaned here. But if you get a little bit more granular there, and as we think about, using the centers that are already doing PCAR, for example? I mean, if they're already treating this patient, they're already trained on the device, I mean, what would be the rationale in continuing to treat a patient that they're going to intervene with anyway with a carotid endarterectomy once you have the standard risk indication? I mean, it just seems like there is no rationale, but maybe I'm being... overly bullish.
spk06: You know, Danielle, this is the question that we ask ourselves every day, right? What is the continued rationale? And, you know, it really comes down to inertia. We're up against a 70-year-old procedure, and physicians who have been doing that procedure for multiple decades, many of them, and we've talked about this inertia before by saying, you know, a mid-career vascular surgeon's done 400, 500 carotid endarterectomies compared to maybe 50 or 60 TCARs, which is a lot, but it pales in comparison. And so it's really about physicians in their own hands, the predictability of TCAR. I think this JAMA paper furthers the evidence on the predictability of TCAR. It's baked into that whole improving of the overall outcomes And so, you know, each and every month that goes by and every publication that is presented in a peer-reviewed journal begins to chip away at that inertia.
spk07: All right. Thanks so much.
spk01: Your next question comes from the line of from Piper Sandler. Your line is now open.
spk02: Hi. Good afternoon and thanks for taking the questions. I had just one quick question on the voluntary recall, Eric and Lucas, and I know you acted out of an abundance of caution there and also did a thorough investigation, and it sounds like you've effectively fenced off the issue and that's behind you. So I guess I was hoping you could just help us better understand what the root cause was of the TIP detachment issue, and then I had a follow-up or two. Thanks. Thanks.
spk06: Yeah, sure. Happy to talk about the root cause, and thanks for joining us, Adam. You know, as we talked about before, the root cause was really human error-centered, having to do with a particular part of the manufacturing process. And, you know, we consider it very good news that a root cause could be identified. You know, often in these recall scenarios, you're looking for kind of a needle in a haystack. You're trying to find some commonality among the lots that have been recalled. But thanks to the excellent work of our engineering team and our quality team, we very quickly zeroed in on a particular human aspect of the process.
spk02: Okay. Thanks for the color there, Erica, and that's great to hear. And for the follow-ups, I guess the next question is on Just the growth outlook for 2021, it feels like the focus has really started to shift more towards increasing utilization in the existing customer base versus training more and more physicians. So the question is, you know, qualitatively, how should we think about the growth of the business in terms of the contribution from increased utilization with existing docs versus new doc ads? And I know you gave that 200 new doc number earlier. But, you know, what does that mix look like? And then, you know, maybe you could level set us on those dynamics in past years in terms of their contributions to growth.
spk03: Yeah, Adam, maybe I'll take that one, and Erica can add any color. You know, we've always said that training new physicians is kind of an investment in the future, not necessarily what's driving the business in the near term. And going back to 2019, we trained – quite a bit more physicians than we'd planned to. So our bias has been, you know, even throughout COVID towards more and more focus on the trained physician base. We're exiting 2020 with just 6% penetration overall. And so there's just a lot of room to run by applying that focus. And the good news is that this is already a concentrated group of docs. And so we're now in a position to benefit from all those prior year training activities. And the fact that we've gotten, you know, a lot of physicians now through their first cases and early part of their experience curve. And as the data and the experience in individual hands accrue, that's where we can, you know, constantly kind of revisit and remind about all the benefits of TCAR against CEA, which they still hold in high regard. And so that's where we have been increasingly applying the focus, and that continues even more so in 2021, as well as, you know, planning for hopefully positive news with FDA on standard risk medications.
spk02: Thanks for the color there. And then just one last one, if I can sneak it in, just, you know, on the P&L, OPEX and Q4 was a little bit above what we were modeling. And I think that was due to the R&D step up. It sounds like you expect continued growth in OPEX in 21. So just trying to, I guess, dial that in a little bit better for our models. So just any quantitative or qualitative color you can give on OPEX spend in 2021 would be great. Thanks so much.
spk03: Yeah, as I said in my prepared remarks, there were some timing-related effects in Q4. That being said, you know, if you annualize that number, you can look at a run rate, and not only are we continuing to invest in certain product and clinical and regulatory activities, but we've got some new ones this year. We're also investing, as we said, in the commercial team over the next two years to a slightly different mix. And so all of those investments should, you know, should incrementally take up OPEX in the 21 quarters and drive long-term growth.
spk02: That's helpful. Thank you.
spk01: There are no questions from participants online. I will turn the call back over to Ms. Erica Rogers for the closing remarks. Please go ahead.
spk06: Thank you all very much for tuning in to the Silk Road earnings call, and we hope you have a terrific 2021.
spk01: Ladies and gentlemen, that does conclude today's conference call. Thank you for participating. You may now disconnect.
Disclaimer